BIOS Capital Management, LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 13, 2026), BIOS Capital Management, LP reported 6 stock positions worth $52.9 million. Its top holding was Actuate Therapeutics (ACTU) at 52.1% of the portfolio, followed by Opus Genetics (IRD, 31.7%) and Cognition Therapeutics (CGTX, 8.6%). Compared with Q4 2025, it added to 1 and reduced 2. The biggest buy was Rein Therapeutics (RNTX, shares +17%) and the biggest sale Lantern Pharma (LTRN, shares −14%).
- Most Recent 13F
- Q2 2026
- Location
- Fort Worth, TX
- CIK
- 0001813845
- Portfolio Value
- $52.9M (Q1 2026)
- SEC Filing
- 0001813845-26-000003 ↗ filed May 13, 2026
Holdings Value
Holdings 6 stocks · $52.9M
| ACTU Actuate Therapeutics Inc. | 52.09% | 10,049,996 | $27.5M | No change |
| IRD Opus Genetics Inc. | 31.70% | 3,683,429 | $16.8M | No change |
| CGTX Cognition Therapeutics Inc. | 8.63% | 6,000,000 | $4.6M | No change |
| RNTX Rein Therapeutics Inc. | 4.87% | 1,982,375 | $2.6M | Add +17.3% |
| LTRN Lantern Pharma Inc. | 2.24% | 864,435 | $1.2M | Reduce -14.4% |
| INAB IN8BIO Inc. | 0.47% | 167,805 | $248K | Reduce -33.8% |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
| RNTX Rein Therapeutics Inc. | Add +17.3% | 4.87% | +2.50 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $41.7M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q1 2026 | 6 | $52.9M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q4 2025 | 6 | $82.6M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q3 2025 | 6 | $88.9M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q2 2025 | 6 | $72.6M | ACTU, IRD, LTRN, RNTX, CGTX |
| Q1 2025 | 6 | $79.2M | ACTU, LTRN, RNTX, CGTX, INAB |
| Q4 2024Amended | 6 | $94.1M | ACTU, CGTX, RNTX, LTRN, INAB |